Drug Database
MI

mite allergy vaccine (Dust mite TOL)

✓ Approved

Laboratorios LETI · 治疗药物

什么是 mite allergy vaccine?

mite allergy vaccine 是一种治疗药物,由Laboratorios LETI研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Oral (PO)、Subcutaneous Injection、Sublingual (SL)/Oral Transmucosal。

药物档案

商品名Dust mite TOL
公司Laboratorios LETI
给药途径Injectable (Others), Oral (PO), Subcutaneous Injection, Sublingual (SL)/Oral Transmucosal
状态Approved

治疗适应症

mite allergy vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

相关研究文献

PubMedNPJ science of food2026-11-17

Multi-omics analysis reveals enhanced antioxidant capacity and altered flavor-associated metabolism in goji leaves infested by the gall mite Aceria pallida.

Li Ya-Nan YN, Wang Zhou-Tong ZT, Wang Yue Y, Shao Ming-Long ML et al.

Goji (Lycium barbarum) leaves are rich in bioactive compounds but highly susceptible to Aceria pallida, which induces gall formation. This study aimed to characterize the metabolic and flavor profile alterations in goji leaves following mite infestation. This study used a comprehensive approach-non-targeted and targeted metabolomics, volatile profiling, and antioxidant assays. Infestation by the goji gall mite triggered a strong defense response, increasing the activities of superoxide dismutase and phenylalanine ammonia-lyase in the phenylpropanoid metabolic pathway by 2.31-fold and 2.67-fold, respectively, and enhancing the specific accumulation of total polyphenols, total flavonoids, key phenolic acids, and carotenoid metabolites. Concurrently, biotic stress enhanced the antioxidant activity and altered flavor characteristics in gall-induced goji leaves. These findings establish goji gall mite as a biotic stress elicitor that improves both antioxidant capacity and sensory quality. This study provides a sustainable strategy for valorizing gall-induced goji leaves as a high-value functional food development.

PMID 43039934
阅读全文 →
PubMedClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2026-11-17

BSACI Guidance on Assessment of Individuals With Allergic and Immunological Conditions on Behalf of the United Kingdom Armed Forces.

Whyte Andrew F AF, Phipps Angelith A, Griffiths Elizabeth E, Arshad Syed Hasan SH et al.

This guideline, developed by the British Society for Allergy and Clinical Immunology (BSACI) Military Working Group, provides clinical guidance for assessing allergic and immunological conditions in UK Armed Forces serving personnel or recruits. The document outlines principles for individualised assessment rather than prescriptive rules, as assessment of these conditions is often nuanced and reliant on a best estimate of risks following individualised assessment. It discusses the unique challenges of military service-including unpredictable exposures, rigorous environments, and limited access to medical care-which necessitate stringent medical standards for recruitment and retention. The guideline addresses the allergic and immunological conditions most frequently encountered, such as food allergies, drug and vaccine hypersensitivities, venom allergies, allergic rhinitis, chronic spontaneous urticaria, idiopathic anaphylaxis, and immunodeficiencies. The role of allergists, immunologists, or other specialists with a role in assessment of these conditions is to provide detailed diagnostic evaluations and risk assessments to inform military occupational health decisions, without making direct judgements on fitness for service.

PMID 43042791
阅读全文 →
PubMedPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2026-11-17

Comment on "Attitudes of caregivers of children labeled with drug allergy after delabeling by provocation tests".

Priyanka, Sharma Ramica R, Reddy Y Madhavi YM

PMID 43040601
阅读全文 →
PubMedBMC public health2026-11-17

Post-introduction evaluation of COVID-19 vaccine deployment in Ghana: lessons learnt to inform future new vaccine introductions and strengthen public health readiness, 2023.

Amponsa-Achiano Kwame K, Shen Angela K AK, Baiden Laryea Eunice E, Carlton Julie Garon JG et al.

On March 2nd, 2021, Ghana, the first country to receive vaccines from the COVAX facility, began its COVID-19 vaccination using a complex multi-phased approach, to reach target populations. We evaluated the vaccine deployment to document best practices challenges and lessons for future new vaccine introductions and public health emergency readiness. We conducted a mixed methods post-introduction evaluation, purposively sampling 36 facilities from 12 districts in six regions. Adapting the World Health Organization's COVID-19 Post-Introduction Evaluation tool, we conducted a cross-sectional survey using a structured questionnaire, reviewed programme records, observed practices, and interviewed purposively selected health workers, immunization managers and partners who supported vaccine deployment. We performed summary descriptive statistics on quantitative data, thematic analysis on qualitative data, and triangulated the results. As of March 2023, more than 70% of the target population (15 years and older) had received at least one dose, while more than 50% had completed the primary series. Vaccine deployment was built on the existing immunisation programme and functional coordinating bodies. Cold chain capacity was revamped with ultra-low-temperature freezers, while 33.3% of surveyed districts adjusted waste disposal systems to accommodate COVID-19 vaccine introduction. Door-to-door delivery and demand generation through varied risk communication and community engagement strategies improved vaccine access. Electronic data platforms were established, surge capacity improved, and healthcare and community workers were trained. Initial unpredictable vaccine supplies limited vaccination efforts. Changing vaccine information affected health workers' ability to engage communities with up-to-date guidance. While vaccine safety monitoring systems were in place, reporting knowledge varied among health workers, and 36% of surveyed facilities had ever documented and reported COVID-19 vaccine-related adverse events following immunisation. Challenges with electronic data systems limited timely access to and use of granular service-delivery data for decision-making. Ghana leveraged existing immunisation and emergency-response systems to make substantial progress in COVID-19 vaccine deployment. Coordination, cold chain expansion, flexible service delivery, demand generation and workforce mobilisation supported implementation. Irregular vaccine supply, data system challenges, variable adverse event reporting, waste management pressure and misinformation challenged deployment. These findings provide lessons for adult immunisation, life-course vaccination and future public health emergency readiness.

PMID 43040294
阅读全文 →
PubMedNorthern clinics of Istanbul2026-11-17

Systemic peptide inhibitor of transendothelial migration administration attenuates microvascular leukocyte adhesion in an ovalbumin-induced mouse model of allergic inflammation.

Sevim Mustafa M, Akbaba Alperen A, Yerli Doganay D, Sulu Ela E et al.

Allergic rhinitis (AR) is driven by type 2 immune polarization and excessive leukocyte trafficking. Current pharmacotherapies act symptomatically rather than at the level of transendothelial migration (TEM). Peptide inhibitor of TEM (PEPITEM) is a B lymphocyte-derived peptide that engages endothelial cadherin-15 to stimulate sphingosine-1-phosphate secretion and inhibit lymphocyte firm adhesion. Although effective in Type 1 autoimmune and metabolic inflammation, PEPITEM has not been examined in Type 2 allergic disease. To evaluate whether systemic PEPITEM administration attenuates systemic leukocyte trafficking in an ovalbumin (OVA)-induced murine AR model, using desloratadine as a clinically established comparator. Thirty-two C57Bl/6 mice (16 males, 16 females; 10-12 weeks; 20-25 g) were randomized to four groups (n=4 per sex per group): control, allergy, allergy+desloratadine (10 mg/kg oral gavage), and allergy+PEPITEM (200 μg/200 μL intraperitoneal). AR was induced by intraperitoneal OVA/alum sensitization (days 1-13) and intranasal 1% OVA challenge (days 22-25). Leukocyte rolling counts, stationary, and adherent leukocytes in mesenteric post-capillary venules were quantified by intravital microscopy (IVM). Peripheral leukocyte differentials were determined by hemogram. One-way analysis of variance was used as the primary analysis. OVA sensitization and challenge increased peripheral lymphocytosis (p=0.0446-0.0059) and eosinophilia (p=0.0019) and significantly elevated stationary leukocytes and adhesion (p=0.0003) in mesenteric venules, while rolling was statistically unchanged. PEPITEM reduced firmly adherent leukocyte density (p<0.05 vs. allergy group) and normalized blood eosinophilia, with effects comparable to those observed in the desloratadine-treated group. Tissue oxidative and inflammatory marker analysis showed limited organ-specific changes; PEPITEM reduced myeloperoxidase activity in the liver (p=0.0158) and colon (p=0.0288), whereas malondialdehyde and glutathione levels were largely unchanged across tissues. In this study, systemic PEPITEM administration reduces systemic leukocyte adhesion and several allergic phenotypes during OVA-driven Type 2 inflammation, with effects of similar magnitude to desloratadine.

PMID 43041745
阅读全文 →
PubMedACI open2026-11-17

Enhancing Human Papillomavirus Vaccine Communication with Mobile Health: Usability Insights from Caregivers and Health Care Providers.

Reisher Elizabeth E, Anyanwu Evangel E, Figliomeni Jonathan J, Honcoop Adrien A et al.

Despite the effectiveness of the human papillomavirus (HPV) vaccine in preventing cancer, uptake remains suboptimal, especially among rural and underserved populations. Digital communication tools such as mobile health (mHealth) applications have the potential to improve access to accurate vaccine information and support shared decision-making. This study aimed to assess the usability, acceptability, and perceived usefulness of a newly developed mHealth app for HPV vaccine communication in comparison to the Centers for Disease Control and Prevention's (CDC) HPV vaccine Web site. Using a mixed-methods design and guided by the Health Belief Model and the mHealth Agile Development and Evaluation Lifecycle, caregivers, and health care providers were randomized to explore both the CDC Web site and the mHealth app in alternating order. Participants were asked to complete a session answering HPV vaccine questions with each tool and completed the mHealth App Usability Questionnaire, Propensity to Trust, and NASA Task Load Index (NASA-TLX) after each session. Qualitative questions were asked after each session to capture additional feedback on items such as navigation and readability. Transcripts were analyzed using inductive thematic analysis. Quantitative results showed no difference between the tools in terms of being easy to use, requiring similar amounts of effort, and trust in the tool. Qualitative themes revealed that participants appreciated the app's streamlined navigation, tailored content, and readability. In contrast, the CDC Web site was seen as credible but often difficult to navigate, especially when searching for nuanced or specific vaccine information. Tailored mHealth tools developed with user-centered design principles may better meet the informational and usability needs of caregivers and health care providers compared with existing web-based resources. These findings support further development and integration of mHealth tools into vaccine communication strategies to enhance HPV vaccine communication.

PMID 43042227
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多mite allergy vaccine